Company Description
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.
It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
The company was founded in 1999 and is headquartered in Paris, France.
| Country | France |
| Founded | 1999 |
| IPO Date | Feb 7, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 222 |
| CEO | Andre Choulika |
Contact Details
Address: 8, rue de la Croix Jarry Paris, 75013 France | |
| Phone | 33 1 81 69 16 00 |
| Website | cellectis.com |
Stock Details
| Ticker Symbol | CLLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001627281 |
| CUSIP Number | 15117K103 |
| ISIN Number | US15117K1034 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Sourdive Ph.D. | Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC and Manufacturing and Director |
| Dr. Andre Choulika Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Arthur Stril | Chief Financial Officer and Chief Business Officer |
| Valerie Cros | Principal Financial Officer and Principal Accounting Officer |
| Jean Charles Epinat Ph.D. | Chief Technological Officer |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
| Marie-Bleuenn Terrier | General Counsel and Secretary of the Board of Directors |
| Pascalyne Wilson | Director of Communications |
| Kyung Nam-Wortman | Executive Vice President and Chief Human Resources Officer |
| Stephan Reynier M.Sc. | Chief Regulatory and Pharmaceutical Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2025 | F-3 | Filing |
| Jun 26, 2025 | 6-K | Report of foreign issuer |
| Jun 26, 2025 | 6-K | Report of foreign issuer |
| May 21, 2025 | 6-K | Report of foreign issuer |
| May 21, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | 6-K | Report of foreign issuer |
| May 6, 2025 | 6-K | Report of foreign issuer |
| Apr 28, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 6-K | Report of foreign issuer |